DTIC-DOME
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
May 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DTIC-DOME is a small-molecule injectable chemotherapy agent approved in 1975 for oncology indications. The specific mechanism of action and approved indications are not publicly detailed in this dataset. This legacy product represents a mature, established therapeutic option in the cancer treatment landscape.
LOE Approaching
Product is in late-stage lifecycle with no current Part D spending data; team size and investment likely focused on operational efficiency rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DTIC-DOME currently shows zero linked job openings, reflecting its mature status and approaching loss of exclusivity. Career opportunities are likely limited to specialized roles in cost management, market access, and operational efficiency rather than commercial expansion.
Brand ManagerCommercial Operations Manager
Worked on DTIC-DOME at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.